Boston Scientific (BSX) versus Its Rivals Head-To-Head Survey

Boston Scientific (NYSE:BSX – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its rivals? We will compare Boston Scientific to related businesses based on the strength of its valuation, dividends, profitability, analyst recommendations, earnings, institutional ownership and risk.

Profitability

This table compares Boston Scientific and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Boston Scientific 16.62% 18.61% 10.58%
Boston Scientific Competitors -269.88% -187.36% -21.77%

Earnings & Valuation

This table compares Boston Scientific and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Boston Scientific $20.07 billion $2.90 billion 18.24
Boston Scientific Competitors $1.87 billion $136.27 million 5.73

Boston Scientific has higher revenue and earnings than its rivals. Boston Scientific is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Boston Scientific has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Boston Scientific’s rivals have a beta of 2.58, suggesting that their average stock price is 158% more volatile than the S&P 500.

Insider & Institutional Ownership

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 0.3% of Boston Scientific shares are owned by company insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Boston Scientific and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific 2 8 20 1 2.65
Boston Scientific Competitors 4320 10604 18410 838 2.46

Boston Scientific currently has a consensus price target of $61.43, suggesting a potential upside of 42.68%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 26.28%. Given Boston Scientific’s stronger consensus rating and higher probable upside, analysts clearly believe Boston Scientific is more favorable than its rivals.

Summary

Boston Scientific beats its rivals on 11 of the 13 factors compared.

Boston Scientific Company Profile

(Get Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.